Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1NET 1Endocrine 1

Conditions

Lymphoma 2Neuroendocrine Tumors 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1Carcinoid Tumor 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
CX 3543 × Clear all
NCT00780663 2011-06-15

Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

Cylene Pharmaceuticals

Phase 2 Completed
25 enrolled
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

NCT00955292 2009-08-10

Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas

Cylene Pharmaceuticals

Phase 1 Terminated
12 enrolled
Lymphoid

Lymphoma

NCT00955786 2009-08-10

Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas

Cylene Pharmaceuticals

Phase 1 Completed
48 enrolled
Lymphoid

Lymphoma

NCT00485966 2008-11-05

Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

Cylene Pharmaceuticals

Phase 2 Withdrawn
25 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡